Video

VIEW 1 and VIEW 2 studies: taking a deeper dive

Rahul Khurana, MD, shares a preview of his ASRS poster based on an analysis of the second year of the VIEW 1 and VIEW 2 studies comparing aflibercept and ranibizumab treatment arms.

Rahul Khurana, MD, highlights the analysis illustrating that there's a lot of variability in clinicians’ management of age-related macular degeneration, and also the treatment needs. There are some patients who need to get treated every four weeks or every eight weeks, but there are also patients that can go longer. The analysis showed that nearly half of these patients could go about 12 weeks or greater. Khurana will present his poster during a reception on July 15 at this year’s American Society of Retina Specialists meeting in New York.

Related Videos
(Image credit: Ophthalmology Times) AGS 2025: Telemedicine and genetics for resource-efficient care with Louis R. Pasquale, MD
(Image credit: Ophthalmology Times) AGS 2025: Two-year data of bio-interventional cyclodialysis with scleral allograft with Leon W. Herndon Jr, MD
(Image credit: Ophthalmology Times) AGS 2025: Aqueous humor outflow improvement after excimer laser trabeculostomy with Clemens Strohmaier, PhD
(Image credit: Ophthalmology Times) AGS 2025: Long-term efficacy and safety of standalone and phaco ELT with Marc Toeteberg-Harms, MD
(Image credit: Ophthalmology Times) Thomas W. Samuelson, MD, shares clinical perspectives on DSLT, SLT, and glaucoma management
© 2025 MJH Life Sciences

All rights reserved.